InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Details About Public Offering, Begins Dosing in Final Phase 2 Trial Cohort
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting the price and size of the public offering it announced earlier this week. According to the company, 24,264,706 units of the company will be sold at a price of $0.34 per unit, resulting in an estimated $8.25 million in gross…